Vol. 18 No. 1 (2017)

A general model for the estimation of societal costs of lost production and informal care in Italy

Lorenzo Pradelli, Gianni Ghetti
- HTML
- PDF

The cost of a combination Anti-Retroviral Therapy (cART) optimization pathway as maintenance therapy in HIV-1 infected patients

Roberto Ravasio, Fabio Rigo, Emanuela Lattuada, Ercole Concia, Massimiliano Lanzafame
- HTML
- PDF
Evaluation of the cost saving potential of introducing Benepali® and Flixabi® on the European and Italian markets

Cristina Negrini, Emi Psachoulia
- HTML
- PDF
A cost-effectiveness analysis of E/C/F/TAF vs three boosted regimens in the Italian context

Lorenzo Pradelli, Giovanni Di Perri, Giuliano Rizzardini, Elisa Martelli, Stefano Giardina, Massimiliano Povero
- HTML
- PDF
Economic implications in inflammatory bowel disease: results from a retrospective analysis in an Italian Centre

Angela Variola, Arianna Massella, Andrea Geccherle, Paolo Bocus, Roberto Tessari, Teresa Zuppini, Roberto Ravasio
- HTML
- PDF
Cost-effectiveness analysis of empagliflozin in the treatment of patients with type 2 diabetes and established cardiovascular disease in Italy, based on the results of the EMPA-REG OUTCOME study

Sergio Iannazzo, Edoardo Mannucci, Odette Reifsnider, Aldo Pietro Maggioni
- HTML
- PDF
Budget impact analysis of dabigatran compared with rivaroxaban in the prevention of the thromboembolic risk in patients with non-valvular atrial fibrillation

Maria Grazia Celeste, Francesca De Marco, Claudio Fresco, Giuseppe Musumeci, Roberto Ravasio
- HTML
- PDF
Varenicline treatment for smoking cessation in high risk patients: a budget impact analysis

Federico Spandonaro, Letizia Mancusi, Barbara Polistena
- HTML
- PDF
Budget Impact analysis of the first-line treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) adult patients

Francesco Mennini, Andrea Marcellusi, Raffaella Viti, Giuseppe Saglio
- HTML
- PDF
Equilibrium between resources and expenditure of health sector of Social Security Fund: a case study of Iran

Azadeh Ahmadi Dashtian, Mohsen Mardali
- HTML
- PDF

Recently approved recombinant factor VIII (rFVIII) for the replacement treatment in patients with hemophilia A in Italy

Daniela Paola Roggeri, Ezio Zanon, Alessandro Roggeri
- HTML
- PDF
[Use of Kovaltry® in patients with Hemophilia A: clinical and economical aspects from the pivotal clinical trials]

Lucia Sara D'Angiolella, Angelo Claudio Molinari, Paolo Angelo Cortesi, Antonio Coppola, Lorenzo Giovanni Mantovani
- HTML
- PDF
[In reference to "Clinical and economic evaluation of the introduction of the combinazion trametinib + dabrafenib in the management of advanced melanoma in the Italian market”]

Matteo Ferrario, Giovanni Giuliani
- HTML
- PDF
[Reply to Letter to the Editor in reference to " Clinical and economic evaluation of the introduction of the combinazion trametinib + dabrafenib in the management of advanced melanoma in the Italian market”]

Lorenzo Pradelli, Paolo Ascierto
- HTML
- PDF

Utilization patterns of complementary and alternative medicine in Australia, Canada and the United States: popularity of dietary supplements, mind-body and manipulative therapies

Marina Luketina Sunjka, Ana Pejcic, Mihajlo Jakovljevic
- HTML
- PDF

Acknowledgement to reviewers (January - December 2017)
- PDF

Vol. 18 No. 1 (2017)

A general model for the estimation of societal costs of lost production and informal care in Italy

The cost of a combination Anti-Retroviral Therapy (cART) optimization pathway as maintenance therapy in HIV-1 infected patients

Evaluation of the cost saving potential of introducing Benepali® and Flixabi® on the European and Italian markets

A cost-effectiveness analysis of E/C/F/TAF vs three boosted regimens in the Italian context

Economic implications in inflammatory bowel disease: results from a retrospective analysis in an Italian Centre

Cost-effectiveness analysis of empagliflozin in the treatment of patients with type 2 diabetes and established cardiovascular disease in Italy, based on the results of the EMPA-REG OUTCOME study

Budget impact analysis of dabigatran compared with rivaroxaban in the prevention of the thromboembolic risk in patients with non-valvular atrial fibrillation

Varenicline treatment for smoking cessation in high risk patients: a budget impact analysis

Budget Impact analysis of the first-line treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) adult patients

Equilibrium between resources and expenditure of health sector of Social Security Fund: a case study of Iran

Recently approved recombinant factor VIII (rFVIII) for the replacement treatment in patients with hemophilia A in Italy

[Use of Kovaltry® in patients with Hemophilia A: clinical and economical aspects from the pivotal clinical trials]

[In reference to "Clinical and economic evaluation of the introduction of the combinazion trametinib + dabrafenib in the management of advanced melanoma in the Italian market”]

[Reply to Letter to the Editor in reference to " Clinical and economic evaluation of the introduction of the combinazion trametinib + dabrafenib in the management of advanced melanoma in the Italian market”]

Utilization patterns of complementary and alternative medicine in Australia, Canada and the United States: popularity of dietary supplements, mind-body and manipulative therapies

Acknowledgement to reviewers (January - December 2017)

adv_fe

PATIENT REPORTED OUTCOMES
An overview

adv_google

adv_gilead

adv_ispor

link_seed

link_call_reprint

link_crossref_similarity_check_cope

link_privacy_cookie_policy

Vol. 18 No. 1 (2017)

Vol. 18 No. 1 (2017)

Methods

Original research

Letter to the Editor

Editorial

Acknowledgement to reviewers

adv_fe

PATIENT REPORTED OUTCOMESAn overview

adv_google

adv_gilead

adv_ispor

link_seed

link_call_reprint

link_crossref_similarity_check_cope

link_privacy_cookie_policy

PATIENT REPORTED OUTCOMES
An overview